Federal Register Notices
View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.
| View | Date Published | Title | Comments Close On | Dates |
|---|---|---|---|---|
| View | Government-Owned Inventions; Availability for Licensing | |||
| View | Government-Owned Inventions; Availability for Licensing | |||
| View | Government-Owned Inventions; Availability for Licensing | |||
| View | Prospective Grant of Exclusive License: Use of Single Chain T-Cell Receptors To Diagnose and Treat Cancer | Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before June 13, 2006 will be considered. | ||
| View | Prospective Grant of an Exclusive License: Therapeutics for the Treatment of Neurodegenerative Disorders | Only written comments and/or license applications which are received by the National Institutes of Health on or before June 13, 2006 will be considered. | ||
| View | Annual Comprehensive List of Guidance Documents at the Food and Drug Administration | We welcome general comments on this list and on agency guidance documents at any time. | ||
| View | Prospective Grant of Exclusive License: The Use of IL13-PE38 for the Treatment of Asthma and Pulmonary Fibrosis | Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before May 22, 2006 will be considered. | ||
| View | Government-Owned Inventions; Availability for Licensing | |||
| View | Prospective Grant of Exclusive License: The Use of HMG-CoA Inhibitors for the Treatment of Adenocarcinomas and Ewing's Sarcoma | Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before May 22, 2006 will be considered. | ||
| View | Prospective Grant of Exclusive License: Dengue Virus Vaccine | N/A | ||
| View | Prospective Grant of Exclusive License: The Use of IL13-PE38 for the Treatment of Asthma and Pulmonary Fibrosis | |||
| View | Prospective Grant of Exclusive License: Device for Cell Culturing, Monitoring and Containment | Only written comments and/or applications for a license received by the NIH Office of Technology Transfer on or before April 24, 2006 will be considered. | ||
| View | Prospective Grant of Exclusive License: Aminoflavone Compounds as Anti-Cancer Agents | Only written comments and/or license applications which are received by the National Institutes of Health on or before April 10, 2006 will be considered. | ||
| View | Prospective Grant of Exclusive License: Food Quality Indicator Device | Only written comments and/or application for a license which are received by the National Institutes of Health on or before April 10, 2006 will be considered. | ||
| View | Prospective Grant of an Exclusive License: “Vasostatin as Marrow Protectant” and “Use of Calreticulin and Calreticulin Fragments To Inhibit Endothelial Cell Growth and Angiogenesis and Suppress Tumor Growth” | Only written comments and/or license applications which are received by the National Institutes of Health on or before April 3, 2006 will be considered. | ||
| View | Prospective Grant of Exclusive License: FDA Approvable Human DNA Diagnostic Test for Endometriosis | Only written comments and/or application for a license which are received by the National Institutes of Health on or before April 3, 2006 will be considered. | ||
| View | Prospective Grant of Exclusive License: FDA Approvable Human Diagnostic for Osteoarthritis | Only written comments and/or application for a license which is received by the NIH Office of Technology Transfer on or before March 21, 2006 will be considered. | ||
| View | Prospective Grant of Exclusive License: Anthrax Lethal Factor Is a MAPK Kinase Protease | Only license applications which are received by the National Institutes of Health on or before March 13, 2006 will be considered. | ||
| View | Prospective Grant of Exclusive License: Software for Predicting Molecular Properties and Pathogen Detection | Only written comments and/or applications for a license received by the NIH Office of Technology Transfer on or before February 28, 2006 will be considered. | ||
| View | Prospective Grant of Exclusive License: Treatment of Cardiovascular Conditions With Nitrite Therapy | Only written comments and/or application for a license, which are received by the NIH Office of Technology Transfer on or before February 28, 2006 will be considered. | ||
| View | Prospective Grant of Exclusive License: Implants for Sustained Ocular Therapeutic Agent Delivery | Only written comments and/or applications for a license received by the NIH Office of Technology Transfer on or before February 28, 2006 will be considered. | ||
| View | Prospective Grant of Exclusive License: Fusion Proteins Comprising Circularly Permuted Ligands | Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before February 28, 2006 will be considered. | ||
| View | Prospective Grant of Exclusive License: Cleaning Mucus From Endotracheal Tubes | Only written comments and/or applications for a license received by the NIH Office of Technology Transfer on or before January 9, 2006 will be considered. | ||
| View | Government-Owned Inventions; Availability for Licensing | |||
| View | Prospective Grant of Exclusive License: North-2'-Deoxy-Methanocarbathmydines as Antiviral Agents Against Poxvirus | Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before December 6, 2005 will be considered. |